Drug intelligence / Profile preview

GB281

Development stage: Preclinical
Lead developer: Genor Biopharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GB281 is a bispecific T-cell engager (BiTE) antibody developed by Genor Biopharma for the treatment of hematologic malignancies. It is engineered to simultaneously bind to the CD20 antigen on malignant B cells and the CD3 receptor on T cells. This dual-targeting mechanism redirects the patient's own T cells to recognize and eliminate CD20-expressing cancer cells. GB281 is part of Genor Biopharma's pipeline of antibody-based biologics, specifically designed to provide a targeted immunotherapy option for patients with B-cell-derived blood cancers.

Targets

CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on GB281.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB281.

Explore the full profile